They are considered “tween players among [some] haematological malignancies.” (53) Up-regulation of PVT1, mediated by MYC, is thought to confer a proliferation advantage to malignant cells, e.g. in acute myeloid leukaemia (AML), acute promyeloid leukaemia (APL), or multiple myeloma (MM) (53). Here, MYC is linked to plasma cell myeloma.